C WorldWide Group Holding A S cut its stake in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 7.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 197,010 shares of the specialty pharmaceutical company’s stock after selling 17,011 shares during the period. C WorldWide Group Holding A S owned approximately 0.06% of Valeant Pharmaceuticals International worth $3,408,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. IFP Advisors Inc boosted its position in Valeant Pharmaceuticals International by 10.6% in the first quarter. IFP Advisors Inc now owns 127,796 shares of the specialty pharmaceutical company’s stock worth $1,410,000 after buying an additional 12,240 shares in the last quarter. Financial Architects Inc boosted its position in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Valeant Pharmaceuticals International by 4.5% in the first quarter. Janney Montgomery Scott LLC now owns 19,573 shares of the specialty pharmaceutical company’s stock worth $216,000 after buying an additional 848 shares in the last quarter. Korea Investment CORP acquired a new position in Valeant Pharmaceuticals International during the first quarter worth $225,000. Finally, Sigma Planning Corp acquired a new position in Valeant Pharmaceuticals International during the first quarter worth $184,000. Institutional investors own 51.14% of the company’s stock.
Valeant Pharmaceuticals International, Inc. (VRX) opened at 13.89 on Friday. The stock’s market cap is $4.83 billion. Valeant Pharmaceuticals International, Inc. has a 12-month low of $8.31 and a 12-month high of $32.74. The stock has a 50 day moving average price of $16.57 and a 200-day moving average price of $13.38.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. During the same quarter in the previous year, the firm posted ($0.88) earnings per share. The company’s revenue was down 7.7% compared to the same quarter last year. On average, equities analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current year.
WARNING: This report was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/08/12/c-worldwide-group-holding-a-s-has-3-41-million-position-in-valeant-pharmaceuticals-international-inc-nysevrx.html.
VRX has been the subject of a number of research analyst reports. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a report on Sunday, July 30th. BidaskClub cut Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Scotiabank lowered their price target on Valeant Pharmaceuticals International from $15.00 to $12.00 and set a “sector perform” rating for the company in a report on Wednesday, April 26th. Vetr cut Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.82 price target for the company. in a report on Monday, May 22nd. Finally, Mizuho reissued an “underperform” rating and set a $8.00 target price (down previously from $9.00) on shares of Valeant Pharmaceuticals International in a research note on Monday, April 17th. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $17.31.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.